Back

Hyperkalemia consequences on the probability of interrupting or lowering renin-angiotensin-aldosterone system inhibitors and risk of hospitalization in patients with chronic cardiovascular conditions

12 May 2024 (11:57 - 12:06)
Organised by: Logo
Congress Presentation Part of: Treating heart failure with diabetes and renal disease Angiotensin-Renin-Bradykinin System HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Santiago Jimenez-Marrero

University Hospital of Bellvitge, Barcelona (Spain)

6 More presentations in this session

Presentation thumbnail
Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and type 2 diabetes. Data from the Swedish Heart Failure Registry and National Diabetes Registry
Doctor F. Musella (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Insulin therapy in patients with heart failure and type 2 diabetes: predictors of use and associations with outcomes. Data from the Swedish Heart Failure Registry and National Diabetes Registry.
Mr M. Biber (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Deciphering mortality risk of antidiabetic medications in well-treated heart failure patients with diabetes mellitus
Assistant Professor I. Colluoglu (Izmir, TR)
Abstract Slides Video
Presentation thumbnail
Survival analysis in heart failure and end-stage chronic kidney disease: a propensity score matched study comparing peritoneal dialysis and hemodialysis
Assistant Professor A. Sahin (Canakkale, TR)
Abstract Slides Video
Presentation thumbnail
Discontinuation and re-initiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction
Ms L. Landucci (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Treating heart failure with diabetes and renal disease
Video

The Event

Event poster

Heart Failure 2024

12 May 2024 11:57 CET
You may be interested in
thumbnail
Congress Presentation
Implications of levels of hyperkalemia in the risk of renin-angiotensin-aldosterone system inhibitors interruption/down-titration and mortality in patients with chronic cardiovascular conditions
thumbnail
Congress Presentation
Challenges of managing hyperkalaemia in HF patients with CKD while maintaining RAAS inhibitor therapy
thumbnail
Congress Presentation
Patiromer use for the treatment of hyperkaliemia in patients with heart failure and chronic kidney disease, real-world experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources